GlobeNewswire: Repros Therapeutics Inc. Contains the last 10 of 155 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:37:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/01/26/1313206/0/en/Repros-Announces-Negative-Opinion-From-the-EMA-for-Enclomiphene.html?f=22&fvtc=4&fvtv=12309Repros Announces Negative Opinion From the EMA for Enclomiphene2018-01-26T21:01:00Z<![CDATA[THE WOODLANDS, Texas, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.®, (Nasdaq:RPRX) ("Repros" or the "Company") today announced that, consistent with the previously disclosed guidance from the European Medicines Agency (EMA), the CHMP (Committee for Medicinal Products for Human Use), a committee of the EMA, has formally issued a negative opinion for the centralized marketing authorization application (MAA) for enclomiphene for the treatment of secondary hypogonadism previously submitted to the EMA by the Company's U.K. subsidiary, Renable Pharma Limited.]]>https://www.globenewswire.com/news-release/2017/12/15/1262953/0/en/Repros-Therapeutics-Inc-Receives-Feedback-Following-an-Oral-Explanation-with-the-European-Medicines-Agency.html?f=22&fvtc=4&fvtv=12309Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency2017-12-15T21:00:00Z<![CDATA[THE WOODLANDS, Texas, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) (“Repros” or the “Company”) today announced that following an Oral Explanation, it has received feedback that a negative opinion is likely to be received in January 2018 from the CHMP (Committee for Medicinal Products for Human Use), a committee of the European Medicines Agency (EMA), for the centralized marketing authorization application (MAA) for enclomiphene for the treatment of secondary hypogonadism previously submitted to the EMA by the Company’s U.K. subsidiary, Renable Pharma Limited.]]>https://www.globenewswire.com/news-release/2017/12/12/1252970/0/en/Repros-Therapeutics-Inc-Announces-Acquisition-by-Allergan-plc.html?f=22&fvtc=4&fvtv=12309Repros Therapeutics Inc.® Announces Acquisition by Allergan plc2017-12-12T11:30:00Z<![CDATA[THE WOODLANDS, Texas, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) (“Repros” or the “Company”) today announced that it has entered into a definitive agreement under which Allergan plc (“Allergan”), through a subsidiary, will acquire Repros for a cash payment of $0.67 per share. The Company’s Board of Directors has unanimously approved the transaction.]]>https://www.globenewswire.com/news-release/2017/11/13/1185173/0/en/Repros-Therapeutics-Inc-Reports-Third-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=12309Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results2017-11-13T13:45:00Z<![CDATA[THE WOODLANDS, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2017.]]>https://www.globenewswire.com/news-release/2017/08/14/1084354/0/en/Repros-Therapeutics-Inc-Reports-Second-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=12309Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results2017-08-14T13:15:00Z<![CDATA[THE WOODLANDS, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2017.]]>https://www.globenewswire.com/news-release/2017/07/17/1047288/0/en/Repros-Announces-Proellex-Development-Program-Will-Remain-on-Partial-Clinical-Hold-by-the-FDA.html?f=22&fvtc=4&fvtv=12309Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA2017-07-17T10:30:00Z<![CDATA[THE WOODLANDS, Texas, July 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.®, (Nasdaq:RPRX) dedicated to treating male and female reproductive disorders, today announced that it received preliminary feedback from the FDA on the Company’s clinical development program for Proellex®, its oral delivery mechanism for telapristone acetate. The Proellex® program will remain on partial clinical hold, and based upon the FDA’s review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development.]]>https://www.globenewswire.com/news-release/2017/05/18/987793/0/en/Repros-Announces-Pricing-of-3-0-Million-Public-Offering-Of-Common-Stock-And-Warrants-To-Purchase-Common-Stock.html?f=22&fvtc=4&fvtv=12309Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock2017-05-18T12:45:00Z<![CDATA[THE WOODLANDS, Texas, May 18, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc (Nasdaq:RPRX) (“Repros” or the “Company”), announced today that it has entered into an underwriting agreement to sell in a public offering 2,744,125 shares of the Company’s common stock (“Common Stock”) and pre-funded Series C warrants to purchase 2,245,875 shares of Common Stock, which will be offered in lieu of Common Stock to those purchasers whose purchase of Common Stock in the offering otherwise would result in the purchaser beneficially owning more than 4.99% of the Company’s outstanding common stock following the completion of the offering (the “Pre-Funded Warrants”).  Also included in the offering are Series A warrants to purchase 3,742,500 shares of Common Stock (the “Series A Warrants”) and Series B warrants to purchase 2,495,000 shares of Common Stock (the “Series B Warrants”) and, together with the Series A Warrants and the Pre-Funded Warrants, the “Warrants”.  There is no established public trading market for the Warrants and the Company does not expect a market to develop in the future. ]]>https://www.globenewswire.com/news-release/2017/05/17/987260/0/en/Repros-Announces-Proposed-Public-Offering-Of-Common-Stock-And-Warrants-To-Purchase-Common-Stock.html?f=22&fvtc=4&fvtv=12309Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock2017-05-17T20:55:00Z<![CDATA[THE WOODLANDS, Texas, May 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) (“Repros” or the “Company”) today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Repros intends to use the net proceeds from the offering for general corporate purposes.]]>https://www.globenewswire.com/news-release/2017/05/09/981357/0/en/Repros-Therapeutics-Inc-Reports-First-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=12309Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results2017-05-09T20:01:00Z<![CDATA[THE WOODLANDS, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2017.]]>https://www.globenewswire.com/news-release/2017/04/17/961302/0/en/Repros-Announces-the-Issuance-of-New-U-S-Patent-Relating-to-Treatment-Using-Off-Drug-Intervals-For-Certain-Uterine-Conditions.html?f=22&fvtc=4&fvtv=12309Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions2017-04-17T13:15:00Z<![CDATA[THE WOODLANDS, Texas, April 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the issuance of a new patent, U.S. Patent number 9,616,074 (the ‘074 patent), that bolsters the Company’s intellectual property relating to Proellex® (telapristone acetate).  The ‘074 patent, which expires in 2027, relates to the use of Selective Progesterone Receptor Modulators (SPRM), in particular Telapristone Acetate (Proellex®) or Ulipristal Acetate, with an Off Drug Interval (ODI) for the treatment of estrogen-dependent hyperproliferative uterine conditions, such as uterine fibroids and endometriosis.  Under the terms of the patent, ODI is defined as daily administration of the SPRM for a period of time, followed by an ODI sufficient for the patient to menstruate and then by another period of administration of the SPRM.]]>